Impact of life-threatening bleeds on health systems: Stewardship and implementation of a novel reversal agent
Monday, May 4th, 2020 | 12:00 pm - 1:00 pm CT
Wednesday, May 6th, 2020 | 1:00 pm - 2:00 pm CT
Please join us for an in-depth look at the impact of life-threatening Factor Xa inhibitor-related bleeds, including the clinical value and available CMS New Technology Add-on Payment (NTAP) reimbursement for a novel, specific reversal agent.
Webinar Topics:
- Unmet need in life-threatening bleeds
- Treatment challenges
- Value of a novel, specific reversal agent
- Available reimbursement for health systems
Presenters:
Sheldon Koenig
EVP, Chief Commercial Officer
Portola Pharmaceuticals
Jeff Myers, MD, PhD
SVP, Medical Affairs
Portola Pharmaceuticals